Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Cash from Investing Activities: 2019-2024

Historic Cash from Investing Activities for C4 Therapeutics (CCCC) over the last 6 years, with Dec 2024 value amounting to -$51.3 million.

  • C4 Therapeutics' Cash from Investing Activities rose 2422.22% to $4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.8 million, marking a year-over-year increase of 360.05%. This contributed to the annual value of -$51.3 million for FY2024, which is 132.38% down from last year.
  • As of FY2024, C4 Therapeutics' Cash from Investing Activities stood at -$51.3 million, which was down 132.38% from $158.3 million recorded in FY2023.
  • C4 Therapeutics' 5-year Cash from Investing Activities high stood at $158.3 million for FY2023, and its period low was -$190.5 million during FY2020.
  • For the 3-year period, C4 Therapeutics' Cash from Investing Activities averaged around $55.2 million, with its median value being $58.4 million (2022).
  • As far as peak fluctuations go, C4 Therapeutics' Cash from Investing Activities slumped by 11,659.57% in 2020, and later skyrocketed by 171.04% in 2023.
  • Over the past 5 years, C4 Therapeutics' Cash from Investing Activities (Yearly) stood at -$190.5 million in 2020, then climbed by 0.61% to -$189.3 million in 2021, then surged by 130.86% to $58.4 million in 2022, then spiked by 171.04% to $158.3 million in 2023, then slumped by 132.38% to -$51.3 million in 2024.